This paper is only available as a PDF. To read, Please Download here.
Abstract
A retrospective cohort using pharmacy and medical claims was analysed to determine whether the differences in efficacy of various inhaled corticosteroids demonstrated in clinical trials lead to differences in costs of care observed in clinical practice. Subjects that had an ICD-9 (493.XX) code for asthma and a new pharmacy claim for inhaled fluticasone propionate 44 mcg (FP), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), budesonide (BUD) or flunisolide (FLU) were identified and followed for 12 months. Annual asthma care charges (pharmacy and medical) over the 12-month observation period were significantly (P<0·03) higher in patients treated with BDP, TAA, BUD and FLU compared to FP, 24%, 27%, 34% and 45% respectively. In addition, patients treated with BDP, TAA, and FLU were associated with significantly (P≤0·005) higher total healthcare (asthma + non-asthma) charges compared to patients on FP, 53%, 46% and 39% respectively. Asthma care and total healthcare charges remained lower for FP after including FP 110 mcg and excluding patients who were extreme cost outliers (±2 ![Math Eq]()
from the mean) in a univariate sensitivity analysis. This analysis supports recent randomized control trials that FP offers a superior efficacy profile at lower asthma care as well as total healthcare charges compared to other inhaled corticosteroids.
from the mean) in a univariate sensitivity analysis. This analysis supports recent randomized control trials that FP offers a superior efficacy profile at lower asthma care as well as total healthcare charges compared to other inhaled corticosteroids.Keywords
References
REFERENCES
- The health economics of asthma and rhinitis. I. Assessing the economic impact.J Allergy Clin Immunol. 2001; 107: 3-8
- Pharmacy and medical claims database documents cost centers for 1993 annual asthma expenditures.Arch Fam Med. 1996; 5: 36-40
- Inhaled steroids and the risk of hospitalization for asthma.JAMA. 1997; 277: 887-891
- Decrease in hospitalizations for treatment of childhood asthma with increased use of anti-inflammatory treatment, despite an increase in the prevalence of asthma.J Allergy Clin Immunol. 1996; 97: 742-748
- Decrease in asthma mortality rate in Israel from 1991–1995: is it related to increased use of inhaled corticosteroids?.J Allergy Clin Immunol. 2000; 105: 71-74
- Low-dose inhaled corticosteroids and the prevention of death from asthma.N Engl J Med. 2000; 343: 332-336
National Institutes of Health, Highlights of the Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, Bethesda, MD, National Institutes of Health (National Heart, Lung, and Blood Institute), 1997, 1, 50
- Fluticasone alone or in combination with salmeterol vs. triamcinolone in asthma.Chest. 1999; 116: 625-632
- A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma.J Allergy Clin Immunol. 1999; 103: 796-803
- Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma.J Allergy Clin Immunol. 1997; 100: 467-474
- Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.Am J Resp Crit Care Med. 1998; 157: 827-832
- Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone.Eur Resp J. 1999; 13: 993-998
- Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.Respir Med. 1999; 93: 603-612
- Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less.Respir Med. 1998; 92: 95-104
- Intranasal corticosteroids for allergic rhinitis: how do different agents compare?.J Allergy Clin Immunol. 1999; 104: S144-149
- Growth in asthmatic children treated with fluticasone propionate.J Pediatr. 1998; 132: 472-477
- Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide.J Pediatr. 1999; 134: 422-427
- Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function.Am J Respir Crit Care Med. 2000; 162: 2053-2057
- Methodological issues in conducting pharmacoeconomic evaluations: Retrospective and claims database studies.Value in Health. 1999; 2: 82-87
- Outcomes analysis in asthma.JAMA. 1997; 278: 1874-1880
- Guidelines for the clinical and economic evaluation of health care technologies.Soc Sci Med. 1986; 22: 393-408
- The use of administrative data to risk-stratify asthmatic patients.Am J Med Qual. 1997; 12: 113-119
- One year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma.J Allergy Clin Immunol. 2001; 107: 94-98
- Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.Respir Med. 2001; 95: 227-234
- Smearing estimate: a nonparametric retransformation method.J Amer Stat Assoc. 1983; 78: 605-610
- SAS Procedures Guild. Version 7. SAS Institute, Cary1998
- Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma.Pharmacoeconomics. 2000; 18: 253-254
- The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey.J Allergy Clin Immunol. 1999; 104: 957-963
- Prescribing Pricing Guide. Medispan, Inc, Indianapolis2000
- Explaining drug spending trends: does perception match reality?.Health Affairs. 2000; 19: 231-239
- Unintended consequences of drug formularies.Am J Health-Sys Pharm. 1996; 53: 2204-2206
Article info
Publication history
Accepted:
August 6,
2001
Received:
April 26,
2000
Identification
Copyright
© 2001 Harcourt Publishers Ltd. Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
